Emerging drugs for diabetic nephropathy

Simona Bruno, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

There is an increasing number of patients with diabetes mellitus in many countries. Diabetic kidney disease, one of its microvascular complications, is also increasing markedly and has become a major cause of end stage renal disease worldwide. Intervention for preventing and delaying the development and progression of diabetic kidney disease is not only a medical concern, but also a social issue. Despite extensive efforts, however, medical interventions thus far are not effective enough to prevent the progression of the disease and the development of end stage renal disease. This justifies attempts to develop novel therapeutic approaches for diabetic nephropathy. Recent insights on its pathogenesis and progression have suggested new targets for the specific treatment of this disease. They include aldosterone, aldose reductase, arachidonic acid metabolites, growth factors, advanced glycosylation end-products, peroxisome proliferator-activated receptors and endothelin. Several other biochemical mediators have been targeted in experimental animal models with the goal to prevent diabetic nephropathy progression, but translation to clinics of these experimental achievements are still limited or lacking.

Original languageEnglish
Pages (from-to)747-771
Number of pages25
JournalExpert Opinion on Emerging Drugs
Volume10
Issue number4
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Diabetic Nephropathies
Pharmaceutical Preparations
Chronic Kidney Failure
Aldehyde Reductase
Peroxisome Proliferator-Activated Receptors
Advanced Glycosylation End Products
Endothelins
Aldosterone
Arachidonic Acid
Disease Progression
Intercellular Signaling Peptides and Proteins
Diabetes Mellitus
Animal Models
Therapeutics

Keywords

  • AGEs
  • Aldose reductase
  • Aldosterone
  • CTGF
  • Diabetic nephropathy
  • Endothelin
  • IGF
  • PPARs
  • Thromboxanes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Emerging drugs for diabetic nephropathy. / Bruno, Simona; Cattaneo, Dario; Perico, Norberto; Remuzzi, Giuseppe.

In: Expert Opinion on Emerging Drugs, Vol. 10, No. 4, 11.2005, p. 747-771.

Research output: Contribution to journalArticle

Bruno, Simona ; Cattaneo, Dario ; Perico, Norberto ; Remuzzi, Giuseppe. / Emerging drugs for diabetic nephropathy. In: Expert Opinion on Emerging Drugs. 2005 ; Vol. 10, No. 4. pp. 747-771.
@article{89295102ca0949969880b8aeb2b1aa0a,
title = "Emerging drugs for diabetic nephropathy",
abstract = "There is an increasing number of patients with diabetes mellitus in many countries. Diabetic kidney disease, one of its microvascular complications, is also increasing markedly and has become a major cause of end stage renal disease worldwide. Intervention for preventing and delaying the development and progression of diabetic kidney disease is not only a medical concern, but also a social issue. Despite extensive efforts, however, medical interventions thus far are not effective enough to prevent the progression of the disease and the development of end stage renal disease. This justifies attempts to develop novel therapeutic approaches for diabetic nephropathy. Recent insights on its pathogenesis and progression have suggested new targets for the specific treatment of this disease. They include aldosterone, aldose reductase, arachidonic acid metabolites, growth factors, advanced glycosylation end-products, peroxisome proliferator-activated receptors and endothelin. Several other biochemical mediators have been targeted in experimental animal models with the goal to prevent diabetic nephropathy progression, but translation to clinics of these experimental achievements are still limited or lacking.",
keywords = "AGEs, Aldose reductase, Aldosterone, CTGF, Diabetic nephropathy, Endothelin, IGF, PPARs, Thromboxanes",
author = "Simona Bruno and Dario Cattaneo and Norberto Perico and Giuseppe Remuzzi",
year = "2005",
month = "11",
doi = "10.1517/14728214.10.4.747",
language = "English",
volume = "10",
pages = "747--771",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging drugs for diabetic nephropathy

AU - Bruno, Simona

AU - Cattaneo, Dario

AU - Perico, Norberto

AU - Remuzzi, Giuseppe

PY - 2005/11

Y1 - 2005/11

N2 - There is an increasing number of patients with diabetes mellitus in many countries. Diabetic kidney disease, one of its microvascular complications, is also increasing markedly and has become a major cause of end stage renal disease worldwide. Intervention for preventing and delaying the development and progression of diabetic kidney disease is not only a medical concern, but also a social issue. Despite extensive efforts, however, medical interventions thus far are not effective enough to prevent the progression of the disease and the development of end stage renal disease. This justifies attempts to develop novel therapeutic approaches for diabetic nephropathy. Recent insights on its pathogenesis and progression have suggested new targets for the specific treatment of this disease. They include aldosterone, aldose reductase, arachidonic acid metabolites, growth factors, advanced glycosylation end-products, peroxisome proliferator-activated receptors and endothelin. Several other biochemical mediators have been targeted in experimental animal models with the goal to prevent diabetic nephropathy progression, but translation to clinics of these experimental achievements are still limited or lacking.

AB - There is an increasing number of patients with diabetes mellitus in many countries. Diabetic kidney disease, one of its microvascular complications, is also increasing markedly and has become a major cause of end stage renal disease worldwide. Intervention for preventing and delaying the development and progression of diabetic kidney disease is not only a medical concern, but also a social issue. Despite extensive efforts, however, medical interventions thus far are not effective enough to prevent the progression of the disease and the development of end stage renal disease. This justifies attempts to develop novel therapeutic approaches for diabetic nephropathy. Recent insights on its pathogenesis and progression have suggested new targets for the specific treatment of this disease. They include aldosterone, aldose reductase, arachidonic acid metabolites, growth factors, advanced glycosylation end-products, peroxisome proliferator-activated receptors and endothelin. Several other biochemical mediators have been targeted in experimental animal models with the goal to prevent diabetic nephropathy progression, but translation to clinics of these experimental achievements are still limited or lacking.

KW - AGEs

KW - Aldose reductase

KW - Aldosterone

KW - CTGF

KW - Diabetic nephropathy

KW - Endothelin

KW - IGF

KW - PPARs

KW - Thromboxanes

UR - http://www.scopus.com/inward/record.url?scp=27844577676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844577676&partnerID=8YFLogxK

U2 - 10.1517/14728214.10.4.747

DO - 10.1517/14728214.10.4.747

M3 - Article

VL - 10

SP - 747

EP - 771

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -